Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309855 | 0.86 | HSP90AA1 (0.40) | CCR8KCNH2MGLLHPGDS | |
| SCHEMBL2362947 | 0.85 | NPC1 (0.43) | GAA | |
| SCHEMBL2361926 | 0.84 | CCR8 (0.38) | CCR8KCNH2MGLLHPGDSCYP1A1 | |
| SCHEMBL3348570 | 0.84 | CCR8 (0.43) | CCR8KCNH2MGLLHPGDSPDK2 | |
| SCHEMBL2362914 | 0.84 | NPC1 (0.38) | CCR8KCNH2GAARBP4PDK2 | |
| SCHEMBL2350049 | 0.83 | LPAR5 (0.42) | CCR8KCNH2MGLLHPGDS | |
| SCHEMBL2361756 | 0.82 | JAK2 (0.42) | CCR8KCNH2GAA | |
| SCHEMBL2350724 | 0.82 | NAPRT (0.43) | CYP3A4CYP1A1 | |
| SCHEMBL3314653 | 0.82 | SPR (0.41) | CCR8KCNH2CYP3A4MGLLGAA | |
| SCHEMBL2362969 | 0.81 | DRD3 (0.42) | CCR8KCNH2MGLLGAAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | claimed |
| EP-2350007-A1 | HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | claimed |
| WO-2010049331-A1 | HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | HCRTR1 1471/4885HCRTR2 3341/4885CCR8 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.